Effect of granulocyte colony-stimulating factor Priming Combined with Low-dose cytarabine and homoharringtonine in Higher Risk myelodysplastic syndrome Patients

Highlights • G-HA has cytarabine, homoharringtonine and granulocyte colony-stimulating factor. • 61% of myelodysplastic syndrome patients treated with G-HA has complete remission. • G-HA is tolerated in patients who cannot undergo hematopoietic cell transplantation

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia research 2016-09, Vol.48, p.57-61
Hauptverfasser:	Wang, Fang-Xia, Zhang, Wang-Gang, He, Ai-Li, Cao, Xin-Mei, Chen, Yin-Xia, Zhao, Wan-Hong, Yang, Yun, Wang, Jian-Li, Zhang, Peng-Yu, Gu, Liu-Fang
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cytarabine - administration & dosage Female G-CSF priming Granulocyte Colony-Stimulating Factor - administration & dosage Harringtonines - administration & dosage Hematology, Oncology and Palliative Medicine Higher risk Homoharringtonine Humans Leukemia, Myeloid, Acute - complications Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - prevention & control Low-dose cytarabine Male Middle Aged Myelodysplastic syndromes Myelodysplastic Syndromes - complications Myelodysplastic Syndromes - drug therapy Neutropenia - chemically induced Pilot Projects Remission Induction - methods Risk Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • G-HA has cytarabine, homoharringtonine and granulocyte colony-stimulating factor. • 61% of myelodysplastic syndrome patients treated with G-HA has complete remission. • G-HA is tolerated in patients who cannot undergo hematopoietic cell transplantation
ISSN:	0145-2126 1873-5835
DOI:	10.1016/j.leukres.2016.07.005